 "Cipla and Russia's Nacimbio join hands for HIV and hepatitis C drugs")
Russia’s National Immunobiological Company (Nacimbio) has entered into an alliance with Cipla Limited for innovative antiviral medical products for HIV & hepatitis C treatment and technology transfer & active pharmaceutical ingredients (API) manufacturing. Nacimbio CEO Nikolay Semenov and Chandru Chawla, Head of Cipla New Ventures, signed the memorandum of understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for hepatitis C treatment.
Subhanu Saxena, MD & global CEO, Cipla Ltd, said, “Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia. We are glad that, as a responsible partner together with Nacimbio we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”
As a part of this agreement, Nacimbio, along with Cipla, will set up a facility in Russia to manufacture antiretroviral drugs. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019, total market share for anti-HIV drugs will increase to 60 percent.
“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017, we will finalise construction and validation of the manufacturing plant together with Cipla Ltd, products will be commercially available in 2018. Total investment in the project will be over Roubles 2.8 billion,” stated Nikolay Semenov, CEO, Nacimbio.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%